Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

No shortage of fresh IPO capital in 2021

  1. Chris Morrison

    1. RA Capital Management, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Biopharmaceutical companies that conducted initial public offerings (IPOs) on global exchanges during 2021 raised more than US$19.2 billion in fresh capital, nearly matching 2020’s record total.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 91-92 (2022)

doi: https://doi.org/10.1038/d41573-022-00018-0

Updates & Corrections

  • Correction 24 January 2022: Tess Cameron was incorrectly listed as a contributing author, and this has now been corrected.

Competing Interests

RA Capital is a registered investment adviser. This article is not intended, and should not be construed as, investment advice or recommendation to invest in any security. Likewise, this article is not intended as a solicitation to invest in any RA Capital product or service. RA Capital may hold long and/or short positions in companies referenced. All companies mentioned were chosen based on their IPOs’ gross proceeds in the subgroups described.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links